Registry-listed formulations

Nadunolimab · chembl:CHEMBL5095365

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

2 source entries across 2 studies. This list may not include all unresolved or historical entries.

CAN04Registry intervention
Linked study entry; product equivalence not established
View study and source
CAN04Registry product
Named ingredient; product remains distinct
Formulation reported by source: SOLUTION FOR INFUSION
Named ingredient; exact form unconfirmed. This mention does not add to the molecule trial count.
View study and source

Success Metrics

Clinical Success Rate

100.0%

Based on 2 completed trials

Completion Rate

100%(2/2)

Active Trials

3(60%)

Results Posted

0%(0 trials)

Phase Distribution

Phase 1

20%

Phase 1/2

60%

Phase 2

20%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Phase 1Safety & dosage

1(20.0%)

Phase 1/2Combined phases

3(60.0%)

Phase 2Efficacy & side effects

1(20.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(3)

Completed(2)

Detailed Status

Recruiting3

Completed2

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 1/2

Trials by Phase

Phase 11 (20.0%)

Phase 1/23 (60.0%)

Phase 21 (20.0%)

Trials by Status

completed240%

recruiting360%

Recent Activity

3 active trials

Showing 5 of 5

recruitingphase_1_2

A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)

NCT06548230

recruitingphase_2

Immunoprevention for High-risk Lung Lesions

NCT07284485

completedphase_1_2

Nadunolimab in Combination With Gemcitabine Plus Carboplatin in Patients With Advanced Triple Negative Breast Cancer.

NCT05181462

recruitingphase_1_2

Combination Immunotherapy for the Treatment of Chemotherapy-refractory Metastatic MSS CRC

NCT07281716

completedphase_1

A Study of the Safety and Tolerance of CAN04 in Combination With FOLFIRINOX in Subjects With Metastatic Pancreatic Ductal Adenocarcinoma

NCT04990037

Clinical Trials (5)

Showing 5 of 5 trials

NCT06548230Phase 1/2

A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)

Recruiting

NCT07284485Phase 2

Immunoprevention for High-risk Lung Lesions

Recruiting

NCT05181462Phase 1/2

Nadunolimab in Combination With Gemcitabine Plus Carboplatin in Patients With Advanced Triple Negative Breast Cancer.

Completed

NCT07281716Phase 1/2

Combination Immunotherapy for the Treatment of Chemotherapy-refractory Metastatic MSS CRC

Recruiting

NCT04990037Phase 1

A Study of the Safety and Tolerance of CAN04 in Combination With FOLFIRINOX in Subjects With Metastatic Pancreatic Ductal Adenocarcinoma